Version May 2024
| Age group and associated conditions | Volume (mL) | Dose HBsAg (mcg) | Recommended schedule | |
| Single-antigen vaccines | ||||
| Recombivax HB | ||||
| Pediatric/adolescent formulation | 18 through 19 years | 0.5 | 5 | 0, 1, and 6 months |
| Adult formulation | ≥20 years | 1 | 10 | |
| Dialysis formulation | Adults on hemodialysis and other immunocompromised adults aged ≥20 years | 1 | 40 | 0, 1, and 6 months |
| Engerix-B | 18 through 19 years | 0.5 | 10 | 0, 1, and 6 months |
| ≥20 years | 1 | 20 | ||
| Adults on hemodialysis and other immunocompromised adults aged ≥20 years | 2* | 40 | 0, 1, 2, and 6 months | |
| Heplisav-B¶Δ | ≥18 years | 0.5 | 20 | 0 and 1 months |
| PreHevbrioΔ◊ | ≥18 years | 1 | 10 | 0, 1, and 6 months |
| Combination vaccine | ||||
| Twinrix (combined HepB-HepA vaccine) | ≥18 years | 1 | 20 | Standard: 0, 1, and 6 months Accelerated: 0, 7, and 21 to 30 days, and 12 months |
HBsAg: hepatitis B surface antigen; HepB: hepatitis B; HepA: hepatitis A.
* This is a double dose of the standard formulation of Engerix-B for patients ≥20 years of age (Engerix-B does not have a separate dialysis formulation).
¶ HepB-CpG (sold as Heplisav-B) is a recombinant yeast-derived vaccine that contains 3000 mcg of immunostimulatory phosphorothioate oligodeoxyribonucleotide as an adjuvant.
Δ There are insufficient data to inform vaccine-associated risks with Heplisav-B and PreHevbrio in pregnancy. Thus, providers should vaccinate pregnant persons needing HepB vaccination with Engerix-B, Recombivax HB, or Twinrix. In addition, data are not available to assess the effects of Heplisav-B and PreHevbrio on breastfed infants or on maternal milk production and excretion.
◊ The mammalian-derived recombinant hepatitis B vaccine (trivalent), sold as PreHevbrio, was approved for use in the United States in December 2021.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
